Why the study?
The study aimed to identify obstructive hypertrophic cardiomyopathy subtypes by partitioning clinical and pathological variables in patients who underwent septal reduction therapy.
Phenotype-based classification identifies three distinct subtypes of obstructive hypertrophic cardiomyopathy with different clinical, pathological, and prognostic features following myectomy.
Answers are grounded in this paper and cite their sources.
May refine post-myectomy risk stratification in obstructive HCM; hypothesis-generating for subtype-specific therapies pending prospective validation.
This study partitioned variables derived from clinical and pathological information in patients who received septal reduction therapy to identify obstructive hypertrophic cardiomyopathy subtypes. Subtype 1 was characterized by a high percentage of sarcomere mutation carriers and the highest interventricular septal thickness. Subtype 2 was featured by left atrial enlargement and a high percentage of patients with atrial fibrillation. Subtype 3 was characterized by a high left ventricular outflow tract gradient, serious inflammatory cell infiltration, and a high incidence of postoperative adverse events. This finding has been well replicated in 2 validation cohorts with short- and long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: